Stockreport

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics, Inc.  (KLRS) 
PDF BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated t [Read more]